| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.8 |